EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.37 | -0.04 | 0.14 |
| FCF Yield | -31.06% | -0.18% | -51.42% | -14.28% |
| EV / EBITDA | -2.65 | -8.69 | -0.84 | -4.24 |
| Quality | ||||
| ROIC | -39.38% | -25.70% | -61.27% | -25.07% |
| Gross Margin | 91.42% | 89.93% | 79.89% | 77.86% |
| Cash Conversion Ratio | 0.96 | -0.03 | 0.64 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.48% | 7.60% | 6.33% | 21.96% |
| Free Cash Flow Growth | -8,001.87% | 97.61% | -33.63% | -239.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.59 | 4.01 | 0.51 | 2.78 |
| Interest Coverage | -10,418.14 | -60.20 | -24.75 | -10.05 |
| Efficiency | ||||
| Inventory Turnover | 1.61 | 1.19 | 2.88 | 2.26 |
| Cash Conversion Cycle | -920.75 | -198.34 | 3.71 | 13.12 |